TrialBlood advances2024

A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.

Reem Karmali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.